HCV treatment uptake in people who have injected drugs — observations in a large cohort that received addiction treatment 1970–1984

References

• Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010;8:280–8; 288.
   PubMed Web of Science ®Google Scholar
• Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677–84.
   PubMed Web of Science ®Google Scholar
• van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584–93.
   PubMed Web of Science ®Google Scholar
• Sylvestre DL, Zweben JE. Integrating HCV services for drug users: a model to improve engagement and outcomes. Int J Drug Policy 2007;18:406–10.
   PubMed Web of Science ®Google Scholar
• Kieran J, Dillon A, Farrell G, Jackson A, Norris S, Mulcahy F, et al. High uptake of hepatitis C virus treatment in HIV/hepatitis C virus co-infected patients attending an integrated HIV/hepatitis C virus clinic. Int J STD AIDS 2011;22:571–6.
   PubMed Web of Science ®Google Scholar
• Lindenburg CE, Lambers FA, Urbanus AT, Schinkel J, Jansen PL, Krol A, et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol 2011;23:23–31.
   PubMed Web of Science ®Google Scholar
• Grebely J, Raffa JD, Lai C, Krajden M, Kerr T, Fischer B, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009;16:352–8.
   PubMed Web of Science ®Google Scholar
• Grebely J, Petoumenos K, Matthews GV, Haber P, Marks P, Lloyd AR, et al. Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: the ATAHC Study. Drug Alcohol Depend 2010;107:244–9.
   PubMed Web of Science ®Google Scholar
• Kielland KB, Skaug K, Amundsen EJ, Dalgard O. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. J Hepatol 2013;58:31–7.
   PubMed Web of Science ®Google Scholar
• Garson JA, Ring CJ, Tuke PW. Improvement of HCV genome detection with "short" PCR products. Lancet 1991;338:1466–7.
   PubMed Web of Science ®Google Scholar
• Furu K, Strøm H, Rønning M, Skurtveit S, Engeland A, Tverdal A. The Norwegian prescription database (NorDB) - A new register for pharmacoepidemiologic research covering a whole nation. Pharmacoepidemiol Drug Saf 2005;14:48.
   Google Scholar
• Bjoro K, Bell H, Hellum KB, Skaug K, Raknerud N, Sandvei P, et al. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study. Scand J Gastroenterol 2002;37:226–32.
   PubMed Web of Science ®Google Scholar
• Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004;40:1260–5.
   PubMed Web of Science ®Google Scholar
• Dalgard O, Bjoro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008;47:35–42.
   PubMed Web of Science ®Google Scholar
• Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol 2007;42:513–21.
   PubMed Web of Science ®Google Scholar
• Veldt BJ, Saracco G, Boyer N, Camma C, Bellobuono A, Hopf U, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004;53:1504–8.
   PubMed Web of Science ®Google Scholar
• Limketkai BN, Mehta SH, Sutcliffe CG, Higgins YM, Torbenson MS, Brinkley SC, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012;308:370–8.
   PubMed Web of Science ®Google Scholar
• Kasahara A, Tanaka H, Okanoue T, Imai Y, Tsubouchi H, Yoshioka K, et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat 2004;11:148–56.
   PubMed Web of Science ®Google Scholar
• Dieperink E, Pocha C, Thuras P, Knott A, Colton S, Ho SB. All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. Dig Dis Sci 2014;59:872–80.
   PubMed Web of Science ®Google Scholar
• Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011;9:509–16.
   PubMed Web of Science ®Google Scholar
• Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut 2007;56:385–9.
   PubMed Web of Science ®Google Scholar
• Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008;33:126–33.
   PubMed Web of Science ®Google Scholar
• Witteck A, Schmid P, Hensel-Koch K, Thurnheer MC, Bruggmann P, Vernazza P. Management of hepatitis C virus (HCV) infection in drug substitution programs. Swiss Med Wkly 2011;141:w13193.
   Web of Science ®Google Scholar
• Charlebois A, Lee L, Cooper E, Mason K, Powis J. Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients. J Viral Hepat 2012;19:836–42.
   PubMed Web of Science ®Google Scholar
• Alavi M, Raffa JD, Deans GD, Lai C, Krajden M, Dore GJ, et al. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver Int 2014;34:1198–206.
   PubMed Web of Science ®Google Scholar
• Grebely J, Genoway K, Khara M, Duncan F, Viljoen M, Elliott D, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 2007;18:437–43.
   PubMed Web of Science ®Google Scholar
• Jerkeman A, Norkrans G, Lidman C, Westin J, Lagging M, Frimand J, et al. Treatment for chronic hepatitis C in a cohort of opiate substitution therapy recipients in three Swedish cities - completion rates and efficacy. Eur J Gastroenterol Hepatol 2014;26:523–31.
   PubMed Web of Science ®Google Scholar
• Dalgard O. New guidelines for investigation and treatment of hepatitis C. Tidsskr Nor Laegeforen 2011;131:15.
   PubMedGoogle Scholar
• Freeman AJ, Law MG, Kaldor JM, Dore GJ. Predicting progression to cirrhosis in chronic hepatitis C virus infection. J Viral Hepat 2003;10:285–93.
   PubMed Web of Science ®Google Scholar
• Kielland KB, Delaveris GJ, Rogde S, Eide TJ, Amundsen EJ, Dalgard O. Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: a longitudinal long-term cohort study. J Hepatol 2014;60:260–6.
   PubMed Web of Science ®Google Scholar
• Blystad H. Hepatitt C. Norwegian Institute of Public Health; 2013. http://www.fhi.no/artikler/?id=82751.
   Google Scholar
• Mathurin P. HCV burden in Europe and the possible impact of current treatment. Dig Liver Dis 2013;45:S314–17.
   Google Scholar
• Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Muhlberger N, et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology 2012;143:974–85.
   PubMed Web of Science ®Google Scholar
• Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013;58:1598–609.
   PubMed Web of Science ®Google Scholar
• Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis 2011;204:74–83.
   PubMed Web of Science ®Google Scholar
• Hellard ME, Jenkinson R, Higgs P, Stoove MA, Sacks-Davis R, Gold J, et al. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med J Aust 2012;196:638–41.
   PubMed Web of Science ®Google Scholar